Dose-escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects With Retinitis Pigmentosa
← catalyst calendarNCT03326336 · readout in 433 d
Sponsored by GenSight Biologics (industry) · SIGHT.PA — their whole pipeline →.
Phase
Phase 1/2
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
10actual
Sites
3
Countries
France, United Kingdom, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2018-09-26 | actual | When the study began enrolling |
| Primary completion | 2027-10-26 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-10-26 | estimated | The whole study's end, after follow-up |
| First posted | 2017-10-31 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Non-syndromic Retinitis Pigmentosa
Intervention
- Combination product: Gene therapy: GS030-DP AND Medical device: GS030-MD
Primary outcome
what the primary-completion date above is the date OFThe safety and tolerability of escalating doses of GS030-DP administered via a single IVT and repeated light stimulation using GS030-MD in subjects with non-syndromic Retinitis Pigmentosa
measured Week 52/Year 1
Permalink · SIGHT.PA's whole pipeline · Catalyst calendar · Every registered study · What changed